The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer

Haiqi Su; Yinan Wang; Xiaopei Chao; Huanwen Wu; Yan You; Shuru Zhao; Feiyue Wang; Bao Sun; Zhen Zhang; Ming Wu; Zicheng Zhao; Lei Li

doi:10.1002/ctm2.70143

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70143 DOI: 10.1002/ctm2.70143

LETTER TO THE JOURNAL

The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer

Haiqi Su ¹^,²^,³
, Yinan Wang ⁴^,⁵
, Xiaopei Chao ¹^,²^,³
, Huanwen Wu ⁶
, Yan You ⁶
, Shuru Zhao ⁷
, Feiyue Wang ⁷
, Bao Sun ⁸
, Zhen Zhang ⁸
, Ming Wu ¹^,^†
, Zicheng Zhao ⁷^,^†
, Lei Li ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Haiqi Su, Yinan Wang, Xiaopei Chao, Huanwen Wu, Yan You, Shuru Zhao, Feiyue Wang, Bao Sun, Zhen Zhang, Ming Wu, Zicheng Zhao, Lei Li. The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer. Clinical and Translational Medicine, 2025, 15(1): e70143 DOI:10.1002/ctm2.70143

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26(13):3239-3247.

[2]	Tumiati M, Hietanen S, Hynninen J, et al. A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients. Clin Cancer Res. 2018;24(18):4482-4493.

[3]	González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391-2402.

[4]	Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.

[5]	Poveda A, Lheureux S, Colombo N, et al. Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis. J Clin Oncol. 2020;38(15):6057-6057._suppl.

[6]	Mutter RW, Riaz N, Ng CK, et al. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol. 2017;242(2):165-177.

[7]	Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984-998.

[8]	Chen D, Shao M, Meng P, et al. GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing. BMC Bioinf. 2021;22(1):562.

[9]	Ford L, Wolford JE, Brown SM, Randall LM. A profile on the FoundationFocus CDxBRCA tests. Expert Rev Mol Diagn. 2020;20(3):285-292.

[10]	Timms KM, Abkevich V, Hughes E, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.